Trials / Completed
CompletedNCT02586168
The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects
The Effect of Gemcabene (CI-1027) on Insulin Sensitivity in Nondiabetic Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- NeuroBo Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcabene 900 mg | Gemcabene 900 mg once daily (QD) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2001-10-01
- Completion
- 2001-10-01
- First posted
- 2015-10-26
- Last updated
- 2020-04-09
Source: ClinicalTrials.gov record NCT02586168. Inclusion in this directory is not an endorsement.